A Phase IIb/IIIa, Randomized Study to Evaluate the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4

Trial Profile

A Phase IIb/IIIa, Randomized Study to Evaluate the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs Ravidasvir (Primary) ; Ribavirin; Sofosbuvir
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Sponsors Pharco Corporation
  • Most Recent Events

    • 06 Apr 2016 Planned End Date changed from 1 May 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
    • 25 Feb 2016 Results presented at the 23rd Conference on Retroviruses and Opportunistic Infections
    • 22 Dec 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top